Our prior study demonstrated that neonatal blood (NB) contained hematopoietic stem and progenitor cells that declined rapidly after birth. To validate that NB is a source of functional stem cells, we characterized this population in terms of cobblestone area-forming cells ( 
Human hematopoiesis is sustained by a population of pluripotent stem cells that are capable of self-renewal and differentiation into all lineages of functional blood cells. During early embryonic development, these stem cells reside in the yolk sac and the aorta-gonad-mesonephros region, and later migrate to the liver, spleen and BM. 1, 2 At birth, CB is rich in early stem and progenitor cells, thus rendering it an important source of hematopoietic cells for the transplant of patients suffering from malignant and non-malignant diseases. 3 Adult hematopoiesis is essentially a BM event and pluripotent stem cells are rarely detected in the adult circulation.
In previous studies, we demonstrated that NB contained a significant number of stem and progenitor cells which declined rapidly after birth. 4, 5 We proposed that small volumes of NB or expanded NB could potentially be used as an adjunct to CB for transplantation. 4 We also performed a successful transplant on a child with ␤-thalassemia major, who received a marginal volume of CB supplemented with NB from his newborn sister. 6 In spite of the presence of early progenitor cells (CD34 + CD38 Ϫ cells and CFU-granulocyte erythroid macrophage megakaryocyte (CFU-GEMM)) and committed progenitor cells (CD34 + cells, CFU-granulocyte macrophage (CFU-GM), burst-forming unit-erythroid (BFU-E)/CFU-E and CFU-megakaryocyte (CFU-MK)) in the NB, we could not confirm that it contributed to reconstituting the BM of the recipient.
The expression of specific cell surface markers and in vitro colony forming assays are well-established procedures routinely used to quantify hematopoietic stem and progenitor cells for clinical transplantation. However, these tests essentially detect early and committed progenitor cells. In this study, we aimed to investigate the presence of pluripotent stem cells in NB and their capacity for homing and providing sustained engraftment in a recipient. We employed an in vitro limiting dilution assay to identify and compare the early stem and progenitor populations in the form of CAFC and LTC-IC in NB and CB. [7] [8] [9] [10] Considering that in vitro assays cannot sufficiently assess the engraftment capacity of human hematopoietic stem and progenitor cells, we used a xenogeneic model, transplanting the cells into NOD/SCID mice. 11 Our previous study demonstrated that the ex vivo expansion capacity of NB was comparable to that of CB. 12 In this study, we further evaluated the SRC in NB after expansion in the presence of early lineage promoting cytokines and a serum-free medium. Our data provided evidence that NB is an alternative source of hematopoietic pluripotent stem cells.
Materials and methods

Neonatal blood and umbilical cord blood collection
NB samples were obtained from near-term or full-term neonates (gestation age 38.3 Ϯ 1.31, range 35.6-40.2 weeks; weighing 3.2 Ϯ 0.12, range 2.0-4.2 kg) during partial exchange transfusion carried out for the treatment of polycythaemia at 6.9 Ϯ 1.2 h (range 1.5-17 h) of life. These infants had hematocrits ranging from 0.70 to 0.79 (mean 0.73 Ϯ 0.092) before exchange transfusion. Partial exchange transfusion was carried out with an indwelling umbilical venous or radial arterial catheter for blood withdrawal, and a peripheral venous catheter for simultaneous replacement with isotonic saline. CB samples were obtained from full-term normal deliveries. All blood samples were collected in sterile tubes containing preservative-free heparin (final concentration 10 IU/ml; David Bull Laboratories, Victoria, Australia). Parental consent was obtained before all blood collections and this study was approved by the Ethics Committee for Clinical Research of The Chinese University of Hong Kong.
Cryopresevation and thawing of neonatal blood and umbilical cord blood
All blood samples were cryopreserved in a controlled-rate freezer (CryoMed, New Baltimore, MI, USA). The cryoprotectant solution contained a final volume of 10% dimethyl sulphoxide (Sigma, St Louis, MO, USA) and 1% human albumin (Baxter Healthcare Corporation, Glendale, CA, USA). Samples were stored in freezing bags (Cryocyte; Nexell, Irvine, CA, USA) in liquid nitrogen.
Blood samples were thawed by direct immersion in a water bath at 37°C. They were then diluted with an equal volume of washing solution containing 5% human albumin, 10% dextran 40 (McGaw, Irvine, CA, USA) in 0.9% normal saline and centrifuged at 400 g for 15 min at room temperature. Thawed cells were resuspended in PBS (Gibco, NY, USA) containing 1% human albumin, 0.6% acid dextrose formula A (Baxter, Deerfield, IL, USA). MNC were prepared by Ficoll-Hypaque density gradient (1.077 g/ml; Amersham Pharmacia, Uppsala, Sweden) and CD34 + cells were enriched by immuno-magnetic cell separation (MiniMACS; Miltenyi Biotec, Gladbach, Germany) according to the manufacturer's protocol. The purities of enriched CD34
+ cells of CB and NB samples were 93.1 Ϯ 1.27% (range 81.3-97.7%) and 91.2 Ϯ 0.84% (range 80.6-96.1%), respectively, as determined by flow cytometry.
Cobblestone area-forming cells and long-term cultureinitiating cells by limiting dilution assays
CAFC and LTC-IC assays were performed for the determination of the proliferative capacity of CB and NB. 9, 10 The murine stromal cell line (M2-10B4; a kind gift from Dr C. Eaves, Terry Fox Laboratory, Vancouver, BC, Canada) was grown to confluency in flat-bottom 96-well plates and irradiated at 30 Gy (Gammacell-1000 Elite Irradiator; MDS Nordion, Kanata, Ontario, Canada). CB or NB samples were added in four dilutions (358, 896, 2240 and 5600 MNC per well) with 30 replicates. The long term culture medium contained IMDM (Gibco) supplemented with 12.5% FCS (Gibco), 12.5% horse serum (Gibco), 100 U/ml penicillin (Sigma), 100 g/ml streptomycin (Sigma), 2 mm l-glutamine (Gibco), 10 Ϫ6 M hydrocortisone (Sigma) and 10 Ϫ4 m ␤-mercaptoethanol (Sigma). These cultures were maintained at 33°C in a humidified atmosphere containing 5% CO 2 with weekly half-medium changes. At week 5, the percentage of wells with one or more CAFC, each containing at least five hematopoietic cells in the stromal layer was determined by inverted phase-contrast microscopy.
The adherent cells from each well were recovered after trypsin (0.25% in PBS; Gibco) digestion for 5 min. These cells, combined with the non-adherent cells were seeded into 200 l methylcellulose medium consisting of 1.3% methylcellulose (Sigma), IMDM, 30% FCS, 1% BSA, 10 ng/ml interleukin (IL)-3, 20 ng/ml stem cell factor (SCF; PeproTech, Rocky Hill, NJ, USA), 100 ng/ml granulocytemacrophage colony-stimulating factor (GM-CSF; Sandoz, Basle, Switzerland) and 2 U/ml erythropoietin (Calig, Zug, Switzerland). After 2 weeks, the presence of hematopoietic colonies was scored and those wells that contained one or more CFU were considered as positive. The frequencies of CAFC and LTC-IC were computed using the L-calc software, version 1.0 (Stem Cell Technologies, Vancouver, BC, Canada).
Ex vivo expansion of enriched CD34
+ cells from neonatal blood
Enriched CD34
+ cells at 2 ϫ 10 4 cells per ml were cultured in 24-well plates ((Becton Dickinson (BD) BDA-3047; Franklin Lakes, NJ, USA) at 37°C and 5% CO 2 for 8 days in the serum-free medium QBSF-60 SFM (Quality Biologicals, Gaithersburg, MD, USA) supplemented with SCF (50 ng/ml), granulocyte colony-stimulating factor (G-CSF, 50 ng/ml; PeproTech), thrombopoietin (TPO, 50 ng/ml; PeproTech) and flt-3 ligand (FL, 80 ng/ml; PeproTech). On day 4, the cultures were demi-depopulated by adding fresh medium and cytokines. On day 8, nucleated cell counts, trypan blue viability assays, CD34
+ cell analysis by flow cytometry and CFU cultures were performed. After washing with IMDM, cultured cells were infused into NOD/SCID mice.
Flow cytometry analysis: Enriched CD34
+ cells or cultured cells were incubated with monoclonal antibodies CD34-fluorescein isothiocyanate (FITC) and CD38-phycoerythrin (PE) or their isotypic controls (Beckon Dickinson) for 20 min at room temperature. These cells were washed with PBS/0.1% BSA and resuspended in PBS/0.1% BSA. 7-aminoactinomycin D (10 l; Pharmingen, San Diego, CA, USA) was added before flow cytometric analysis by a FACScan instrument using the Lysis II software (BD). Thirty thousand events were acquired for each sample and 7-aminoactinomycin D positive cells (non-viable) were gated out during data analysis.
Progenitor cell assay: 3 ϫ 10 3 CD34 + cells or cells expanded for 8 days were plated in triplicate in methylcellulose (1.3%) medium containing IMDM supplemented with 30% FCS, 1% BSA, 10 ng/ml IL-3, 20 ng/ml SCF, 2 U/ml erythropoietin and 100 ng/ml G-CSF as described previously.
12-14 These cultures were incubated in a humidified atmosphere at 37°C and 5% CO 2 and evaluated for CFU-GM, BFU-E/CFU-E and CFU-GEMM after 14 days.
CFU-MK were assayed in a plasma clot system. 15 Briefly, 3 ϫ 10 3 enriched or expanded CD34 + cells were incubated in duplicate in IMDM medium composed of 10% bovine plasma (Gibco), 10 Ϫ4 m ␤-mercaptoethanol, 1% BSA, 10% FCS, 10% CaCl 2 (0.34 mg/ml), 50 ng/ml TPO and 20 ng/ml IL-3. After 12 days of culture, the clots were fixed with 1% paraformaldehyde (Gibco) in PBS and airdried. Immunofluoresence detection was performed after staining with monoclonal antibody CD61-FITC (Dako, Boston, MA, USA). A CFU-MK was identified as a cluster of three or more strongly stained CD61-positive cells examined under a fluorescence microscope (LEITZ DMRD, Leica, Germany).
Transplantation of NOD/SCID mice
The NOD/SCID mouse transplant model was established as reported previously. 16, 17 NOD/LtSZ-scid/scid mice were purchased from The Walter and Eliza Hall Institute of Medical Research (Victoria, Australia), bred and maintained in the Laboratory Animal Services Centre at the Chinese University of Hong Kong. Animals were handled under sterile conditions and maintained in microisolator cages. All procedures were approved by the Animal Research Ethics Committee of the Chinese University of Hong Kong. Mice at 6 to 8 weeks of age were exposed to 300 cGy of total body irradiation from a 137 Cs source (Gammacell-1000). Within 24 h, the animals were anesthetized with a mixture of ketamine (50 mg/kg; Apharmo, Arnhem, The Netherlands) and xylazine (25 mg/kg; Bayer, Leverkusen, Germany) administered intraperitoneally. They were then given a single intravenous injection of enriched CD34
+ cells (2 ϫ 10 4 or 4 ϫ 10 4 CD34 + cells in 0.2-0.4 ml IMDM with 5% FCS) from CB (n = 6), NB (n = 12) or the progenies of ex vivo expanded NB samples (n = 8). The mice were killed 6 weeks post transplant for the assessment of huCD45 + cells and subsets in their BM, PB and spleen.
Evaluation of human cell engraftment by flow cytometry:
Single cell preparations of mouse femoral BM were resuspended in PBS containing 5% FCS. PB was collected by heart puncture. Spleen cells were homogenized in PBS containing 5% FCS. Cell suspensions were first incubated for 5 min with 5% human serum supplemented with 3 mg/ml
Bone Marrow Transplantation of an anti-mouse Fc receptor antibody (2.4 G2; BD) for preventing non-specific binding. Red blood cells were lyzed with 0.83% ammonium chloride for 5 min. After washing and resuspension in PBS containing 5% FCS, cell samples at 5 ϫ 10 5 /100 l were incubated with mouse anti-human CD45-phycoerythrin-cyanine 5-succinimidylester (PC5) antibody (Immunotech, Marseille, France) and 10 g/ml propidium iodide (Sigma) for 20 min in the dark at room temperature. Specific subsets of human hematopoietic cells were identified when BM cells contained more than 3% of human CD45
+ cells. Cell samples were stained with CD45-PC5, propidium iodide, CD34-FITC (BD), CD33-FITC (BD), CD14-FITC (BD), CD19-FITC (BD) or CD61-FITC (Dako). The control tubes contained the respective isotypic antibodies and propidium iodide. All antibodies were previously selected to show no cross-reaction with the NOD/SCID mouse surface antigens. 17 After washing with PBS, 30 000 to 70 000 events were acquired for each sample and non-viable cells (propidium iodide positive) were gated out during data analysis.
Human CFU assay: BM cells harvested from each mouse were plated in human-specific CFU cultures. 17, 18 Before plating, the mouse BM cells were incubated for 4 to 8 h to remove adherent, murine stromal cells that might secrete murine cytokines. 1 ϫ 10 5 BM cells from each recipient mouse were cultured in triplicate in methylcellulose containing 30% FCS, SCF (20 ng/ml), IL-3 (10 ng/ml), GM-CSF (100 ng/ml), and erythropoietin (2 U/ml). BFU-E/CFU-E, CFU-GM and CFU-GEMM colonies were counted at day 14 on the basis of standard morphological criteria. Pilot studies have demonstrated that BM cells from irradiated mice without human stem cell infusion yielded cell clusters on day 7 cultures, but these clusters were reduced to scattered cells on day 14. For the CFU-MK assay, the plasma-clot system was performed in duplicate. 1 ϫ 10 5 cells were cultured for 14 days in 35 mm plates with 1 ml IMDM containing 10% BSA, 10 Ϫ4 m ␤-mercaptoethanol, 10% FCS, 10% bovine plasma (Sigma), 0.34 mg/ml CaCl 2 , 50 ng/ml TPO and 20 ng/ml IL-3 as described previously. 16 After staining with anti-human CD61-FITC antibody (Dako), CFU-MK was scored under a fluorescence microscope.
Analysis of human alpha-satellite DNA:
The detection of an 850-bp fragment of the alpha-satellite DNA of human chromosome 17 was performed by PCR analysis. 19 Genomic DNA from mouse BM was isolated from 3-5 ϫ 10 6 cells by using the QIAamp Blood Kit (Qiagen, Hilden, Germany) in a final volume of 200 l. The 5Ј primer (5Ј GGG ATA ATT TCA GCT GAC TAA ACA G 3Ј) and the 3Ј primer (5Ј TTC CGT TTA GTT AGG TGC AGT TAT C 3Ј) of the sequence HSSATA17 (Gene Bank accession No. M13882) were used in the PCR amplification. The reaction mixture (25 l) contained 200 m each of the respective nucleotides, 250 nm of each primer, 2 mm MgCl 2 , and 125 ng of genomic DNA. Amplification conditions were as follows: 94°C for 10 min, then 35 cycles at 94°C for 1 min, 66°C for 1 min, and 72°C for 1 min, followed by extension at 72°C for 10 min. Four l of the product was electrophoresed on a 1.2% agarose gel and visualized under UV-light after staining with ethidium bromide. Genomic DNA samples from human PB and BM cells from untreated NOD/SCID mice were processed in parallel as controls.
Statistical analysis
This was performed using the SigmaStat software (Jandel Scientific Software, San Rafael, CA, USA). Treatment groups were compared by the Analysis of Variance and the t-test or Mann-Whitney rank sum test, whichever was appropriate. The survival rates of NOD/SCID mice were analyzed using the 2 test. All results were expressed as mean Ϯ standard error of mean (s.e.m.). A P value of р0.05 was considered to be statistically significant.
Results
Frequencies of CAFC and LTC-IC in neonatal blood and umbilical cord blood mononuclear cells
By limiting dilution assays, the frequencies of CAFC in NB (n = 6) and CB (n = 7) were 30.2 and 37.1 per 1 ϫ 10 5 MNC and those of LTC-IC were 28.6 and 31.0 per 1 ϫ 10 5 MNC, respectively. There were no significant differences between the quantities of these early progenitor cells in NB and CB, although a trend of more CAFC was observed in the latter (Figure 1 ).
Ex vivo expansion of neonatal blood
The mean purity of enriched CD34
+ cells from thawed neonatal blood (n = 9) was 93.2 Ϯ 0.67% (range: 88.4-96.1%). After 8 days of liquid culture in the serum-free medium QBSF-60 SFM and the cytokine combination of TPO + SCF + FL + G-CSF, cell viability was 94.5 Ϯ 0.65% (range 89.8-97.1%) as determined by trypan blue exclusion assay.
Total nucleated cells (NC), CD34
+ cells, and progenitors of the myeloid (CFU-GM), erythroid (CFU-E/BFU-E) and megakaryocytic (CFU-MK) lineages were significantly + cells in the high dose of CB when compared to the low dose (P = 0.006). The engraftment of NB was significantly lower than that of CB (high dose, P = 0.012) and higher than that of expanded NB (low dose, P = 0.045).
engraftment of CD45
+ cells when compared to NB (P = 0.012 for high dose groups) and expanded NB (P = 0.022 for low-dose groups and 0.003 for high-dose groups). Engraftment of NB appeared to be reduced after 8 days of expansion (P = 0.045 for the low-dose groups).
Human colony-forming units in the bone marrow of NOD/SCID mice:
The engraftment profiles of total CFU in the BM of NOD/SCID mice were in line with those of huCD45 + cells (Figure 4) . Significantly more CFU were demonstrated in the high-dose CB group when compared to the respective NB group (P = 0.008). Significant differences were not observed between the NB groups with or without expansion. The CFU were essentially composed of CFU-GM (mean range 79.9-86.1%). In addition, multi-lineage colonies BFU-E/CFU-E (10.2-15.1%), CFU-MK (3.02-3.37%) and CFU-GEMM (2.82-5.75%) were consistently present. There were no significant differences in the representation of different CFU populations between the CB, NB and expanded NB groups.
Human CD45
+ cell subsets in the bone marrow of NOD/SCID mice: For the BM samples that contained more than 3% huCD45 + cells, multi-lineage development of hematopoietic cells from the input CD34
+ populations was further analyzed by three-color flow cytometry ( Figure 5 Engraftment of colony-forming units in the bone marrow of NOD/SCID mice. BM cells harvested from each mouse were plated in methylcellulose medium and CFU were counted after 14 days on the basis of their morphology. There were significantly more CFU in the high dose CB when compared to the respective NB group (P = 0.008).
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Detection of human cells in the bone marrow of NOD/SCID mice by PCR analysis:
The semi-quantitative PCR analysis of human cell engraftment in the BM of recipient mice was in agreement with flow cytometry results. Using a combination of standard human PB and mouse BM cells, we were able to confirm low engraftment (0.1-1%) of human cells in the recipients (Figure 7) .
Engraftment of human CD45
+ cells in the spleen and peripheral blood of NOD/SCID mice: HuCD45 + cells were consistently detected in the spleen and PB, although in lower proportions when compared to those in the BM of the recipient mice (Figure 8) . In both tissues, CD45
+ cell levels were significantly lower in NB after 8 days of culture (P Ͻ 0.05).
Discussion
Our data demonstrated that NB contained a significant quantity of early progenitor cells in the forms of CAFC and LTC-IC. The levels of these cells in CB were in general agreement with those reported by other researchers. 20, 21 CAFC and LTC-IC enumerate the ability of primitive progenitor cells to generate CFU after a prolonged period in culture. Week 6 CAFC and LTC-IC have been correlated with the long-term repopulating ability of hematopoietic cells in NOD/SCID mice and in human transplants. 22, 23 By limiting dilution assays, the proportions of CAFC and LTC-IC were similar in NB and CB, again demonstrating that these progenitor cells remain in the circulation of neonates shortly after birth.
Using the semi-quantitative NOD/SCID mouse model, we demonstrated that NB and CB possessed the capacity of reconstituting the BM of recipient animals. The engrafted cells were functional and differentiated into the mature myeloid, erythroid, megakaryocytic and B lymphoid lineages. T lymphocytes were not detected, possibly because NOD/SCID mice are known to have defective T cell development. In line with other studies, huCD45
+ cells were detected in the spleen and PB but the proportions were lower than those in the BM. 22, 24 The engraftment capacity of NB, in terms of CD45 + cells, appeared lower than that of CB, demonstrating that SRC might be decreased in the PB of neonates. However, we have to take into consideration the delayed collection of NB samples (mean 6.9 h after birth), at which time the CD34 + cells would have declined significantly as shown in our previous studies. 4, 5 Our data appeared to indicate that the changes of CAFC, LTC-IC and SRC levels from the CB to the NB stage were not completely in parallel. The kinetics of CAFC, LTC-IC and SRC populations in the circulation of neonates has not been reported. The lack of correlation between SRC and expanded CD34
+ cells, CFU and LTC-IC have been demonstrated by various groups. [25] [26] [27] In spite of the suggestions that human CFU and week-6 CAFC/LTC-IC assays detect highly overlapping populations, 22, 23 it remains unclear
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Ex vivo expansion of cord blood stem cells has been suggested as a strategy to increase the quantity of progenitor cells required for a successful transplant. 28 Some clinical improvements have been observed in transplant patients infused with expanded BM and cytokine-mobilized PB stem cells. 29, 30 In previous studies, we demonstrated that NB and CB had similar ex vivo expansion capacity, which was significantly higher than that of BM cells. In addition, we reported the rapid expansion of NB after 7 days of culture, in comparison with the 14 days required for expanding CB and BM. 12 In this study, we expanded cryopreserved and thawed NB at a condition optimized for clinical appli- cations, using TPO, SCF, FL and G-CSF in a serum-free medium. 16 Our results demonstrated that NB was significantly expanded to produce early and committed progenitor cells of the myeloid and megakaryocytic lineages. More significantly, SRC were present in the expanded product as revealed by huCD45 + cells in the BM, spleen and PB of the recipients, although in a reduced quantity. The high proportions of CD14 + cells and CD33 + cells in the BM of mice infused with NB and expanded NB, respectively suggested that these cells might improve neutrophil engraftment in a clinical transplant setting.
In summary, we provide the first evidence that NB collected shortly after birth contain substantial levels of functional stem cells as indicated by CAFC, LTC-IC and SRC assays. These findings substantiate NB as a novel source of hematopoietic stem cells. The strategy and ethical concerns of infusing a small volume of NB or expanded NB as the supplement to a marginal volume of CB for sibling transplant have been raised in previous studies 4, 12 and deserve further consideration.
